Bedrijfsoverzicht
Vericel Corporation is a commercial-stage biopharmaceutical entity dedicated to the research, development, manufacture, and distribution of cellular therapies and specialty biologic products specifically for the sports medicine and severe burn care markets within North America. The company operates within the Healthcare sector, functioning specifically in the Biotechnology industry, which defines its operational focus on biological agents and advanced therapeutic technologies. In terms of scale, the entity boasts a market capitalization of $1.72B, generates annual revenue of $276.26M, and employs 398 individuals. These valuation and revenue figures indicate that the company has achieved significant commercial traction, transitioning from early-stage research to a revenue-generating phase with a substantial asset base and workforce sufficient to support complex biologic production and distribution networks.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $276.26M with a corresponding net income of $16.52M and an EBITDA of $22.59M. The substantial gap between the total revenue of $276.26M and the net income of $16.52M reveals a cost structure where operating expenses, including research and development, sales, and general administrative costs, consume approximately 94% of gross revenue before arriving at the bottom line. The free cash flow stands at $16.05M, which provides the organization with essential financial flexibility to fund ongoing research projects, maintain manufacturing facilities, and manage operational expenditures without relying on external financing. Profitability analysis shows a gross margin of 74.4%, an operating margin of 24.1%, and a profit margin of 6.0%, indicating that while the core production of biologic products is highly efficient, significant overhead costs are required to maintain the biotechnology business model. The company holds $137.50M in cash against $96.89M in debt, resulting in a debt-to-equity ratio of 27.32, which suggests a conservative balance sheet with ample liquidity to cover obligations. Short-term liquidity is robust, evidenced by a current ratio of 5.03, meaning the company possesses more than five times the current assets necessary to meet its short-term liabilities. Management effectiveness is reflected in a return on equity of 5.1% and a return on assets of 1.5%, metrics that highlight the capital-intensive nature of the biotechnology sector where high asset bases and equity levels are typical, yet absolute return percentages remain modest relative to the revenue generated.
Waarderingsbeoordeling
Valuation metrics indicate a trailing P/E ratio of 105.31 and a forward P/E of 41.86. The significant disparity between these two figures implies that the market expects a substantial improvement in earnings trajectory, as the forward multiple is less than half the trailing multiple. The price-to-book ratio is recorded at 4.81, which indicates that the market values the company at a substantial premium over its net asset book value, reflecting the intangible value of intellectual property and future growth potential inherent in biotechnology firms. Alternative valuation metrics include a price-to-sales ratio of 6.21 and an EV/EBITDA of 73.94, figures that suggest the stock is priced significantly higher than traditional industrial peers due to the high-growth expectations associated with the cellular therapy market. Regarding trading range, the 52-week high is $45.97 and the 52-week low is $28.95; without the specific current share price provided in the source facts, the exact percentage distance from the high cannot be calculated, but the range demonstrates the volatility observed within the fiscal year. The beta value is 1.21, which indicates that the stock's price volatility is 21% higher than the broader market, suggesting that the stock will likely experience larger price swings than the S&P 500 during periods of market turbulence.
Growth & Income
Revenue growth year-over-year is 23.3%, while earnings growth year-over-year is 18.9%, indicating that earnings are growing slightly slower than revenue. This divergence implies that while the top line is expanding rapidly, the company is still managing the integration of new revenue streams or controlling costs to ensure profitability scales proportionally with sales volume. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning that all net income is retained within the company rather than distributed to shareholders. This strategy aligns with the biotechnology industry standard where companies reinvest earnings into research and development, manufacturing capacity, and commercial expansion to drive future growth rather than providing immediate income to investors. The overall growth and income profile is characterized by strong double-digit expansion in both revenue and earnings, coupled with a zero-dividend policy that prioritizes capital allocation toward innovation and market penetration in the sports medicine and burn care sectors.